Upadacitinib for ulcerative colitis and pyoderma gangrenosum in a patient with schizophrenia on long-term risperidone: A case report

Figure 1 Colonoscopy of the patient. Diagnosis: Ulcerative colitis E3 mesalazine = 2 and ulcerative colitis endoscopic index of severity = 5) on April 1, 2024.

Figure 2  Skin damage and therapeutic effects.

Figure 3 Colonoscopy re-examination. Diagnosis: Ulcerative colitis E3 mesalazine = 0 and ulcerative colitis endoscopic index of severity = 1) on August 12, 2024.

Figure 4 Treatment process of the patient during the induction therapy. UC: Ulcerative colitis; ASA: Aminosalicylic acid; SFS: Stool frequency score; RBS: Rectal bleeding score; MES: Mayo endoscopic score; FC: Fecal calprotectin; PG: Pyoderma gangrenosum; SCZ: Schizophrenia; UPA: Upadacitinib; ADA: Adalimumab; SC: Subcutaneous injection; AE: Adverse events.